A 40-year-old male presented with hypersomnia, dysphagia, and difficulties in eye opening, voiding, and gait for 2 weeks. His symptoms were gradually progressing from the onset of drowsiness to the full body, and he complained that his limb muscles became rigid. The patient had experienced similar neurological symptoms 8 years previously, but a definitive diagnosis was not made at that time despite an extensive evaluation. It was notable that these previous neurological symptoms have improved over several months without specific treatment. A neurological examination revealed bilateral ptosis ( Fig. 1) , increased deep tendon reflex in both lower extremities, and spastic gait. However, his horizontal and vertical eye motions and the strength and sensations in all extremities were normal. The findings of serological investigations including infectious condition and thyroid disorder were unremarkable, with negativity for autoantibodies (antinuclear antibody, antiganglioside, acetylcholine receptor, anti-Hu, anti-Yo, anti-Ri, antiamphiphysin, anti-Ma2, and antiglutamic acid decarboxylase). A cerebrospinal fluid (CSF) analysis showed a normal white blood cell count (0/mm 3 ) with no red blood cells. The glucose and total protein concentrations in the CSF were 76 mg/dL (blood glucose level: 98 mg/dL) and 46.6 mg/dL, respectively. Repeated nerve conduction studies, ice eye tests, and measurements of acetylcholine receptor antibody also produced normal findings, as did magnetic resonance imaging of the brain and spine. The findings for tumor markers and computed tomography of the chest and abdominopelvic area for suspicion of paraneoplastic disorder were unremarkable.
presence of antibodies that bind extracellularly to GlyRs suggest that this is an autoantibody-mediated disease that will respond to immunotherapies. 8, 9 Most cases show improvement with corticosteroids and intravenous immunoglobulin and plasmapheresis, but relapse may occur, 10 and so maintenance immunotherapy may be required. Previous studies have used cyclophosphamide, rituximab, azathioprine, or mycophenolate for ongoing immunotherapy; in our case, azathioprine produced good results. Many clinicians advocate starting immunotherapy immediately upon clinical suspicion, as in the present case. It is therefore important to recognize the clinical features of PERM early, and prompt examination of GlyR antibodies should be performed.
In conclusion, we have reported the first Korean case of PERM that was successfully treated with the combination of steroids and azathioprine. We emphasize that clinicians should be aware of the clinical symptoms of PERM in order to ensure its early diagnosis and treatment.
